Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of Intermittent Explosive Disorder, neuropsychiatric symptoms in neurodegenerative diseases, PTSD, and other affective disorders. Vasopressin 1a receptor antagonists represent a novel mechanism of action for addressing these indications. The Company completed a Phase II clinical trial with its lead compound, SRX246, for the treatment of Intermittent Explosive Disorder in adults. The primary endpoint and exploratory goals of the trial were achieved. Two additional Phase II clinical trials launched for the treatment of irritability in Huntington’s Disease Patients and for the treatment of PTSD.